Diagnosed with cancer
after taking Zantac?
Get a Free Consultation
Zantac Lawsuits: Carcinogen Prompts Recall
ALERT: April 1, 2020 – “The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine (Zantac) drugs from the market immediately.”
Since the 1980s, ranitidine (brand name: Zantac) has been associated with NDMA. While Zantac is not contaminated with NDMA, it contains nitrite (N) and dimethylamine (DMA). Combined, they form the carcinogen NDMA.
The Food and Drug Administration (FDA) was notified in June of 2019 that routine testing done in Valisure’s labs had linked Zantac to N-nitrosodimethylamine (NDMA). FDA’s own testing found unacceptable levels of NDMA in Zantac.
“The results [of several case–control studies and one cohort study] are supportive of the assumption that NDMA consumption is positively associated with either gastric or colorectal cancer.” (World Health Organization)
On April 1, 2020, the FDA issued a recall on Zantac. In addition to NDMA concerns, “the agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures may result in consumer exposure to unacceptable levels of this impurity.”
If you have been diagnosed with cancer after taking Zantac regularly, please contact us immediately by calling 504-523-2434 or filling out an online Contact Form for a FREE Consultation.
Possible side-effects include:
Bladder cancer
Colon and rectal cancer
Esophageal cancer
Intestinal cancer
Kidney cancer
Liver cancer
Lung cancer (non-smokers)
and more
Cancer diagnosis after taking Zantac?
FDA calls for heartburn drug Zantac to be pulled from market immediately
Zantac | CNN | Jacqueline Howard | April 1, 2020 &
02 April, 2020
FDA orders all Zantac heartburn products off store shelves
Zantac | NBC News | Erika Edwards | April 1, 2020
02 April, 2020
FDA Wants All Ranitidine Products Off the Market
Ranitidine | MedPage Today | Nicole Lou | April 1,
02 April, 2020
Sanofi recalls popular heartburn drug Zantac as FDA investigates probable carcinogen
Sanofi | USA TODAY | Ken Alltucker | October 18, 2
22 October, 2019
Why Choose Peiffer Wolf?
We handle cases that change lives.
Peiffer Wolf is committed to making sure that the companies that release harmful drugs or medical devices onto the market are held accountable for their wrongful conduct. Our firm’s Pharmaceutical and Medical Devices practice is led by Attorney Daniel Carr, who has represented thousands of clients from across the United States in cases related to pharmaceutical products and medical devices, including litigations involving Essure, Truvada, Low-T, Xarelto, Pradaxa, ASR hip implants, TVM, Actos, Invokana, Onglyza, and others.
With offices in New York, California, Louisiana, Missouri and Ohio, we have the size, experience, resources and leverage to prosecute complex cases against major corporations nationwide. We attribute our history of success to the sophistication, experience, and professionalism of our widely respected lawyers.